Dan G Duda Selected Research

cediranib (AZD2171)

1/2017	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.
4/2016	Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
10/2015	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
11/2013	Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
3/2013	Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
1/2011	Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.
6/2010	Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
7/2009	A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
5/2009	Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
1/2007	AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dan G Duda Research Topics

Disease

125	Neoplasms (Cancer) 02/2022 - 01/2002
30	Hepatocellular Carcinoma (Hepatoma) 02/2022 - 06/2009
25	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 01/2007
23	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2003
15	Breast Neoplasms (Breast Cancer) 11/2021 - 01/2006
12	Hypoxia (Hypoxemia) 01/2022 - 05/2013
11	Rectal Neoplasms (Rectal Cancer) 08/2012 - 02/2004
9	Brain Neoplasms (Brain Tumor) 01/2021 - 04/2009
8	Inflammation (Inflammations) 12/2020 - 04/2004
7	Pancreatic Neoplasms (Pancreatic Cancer) 09/2020 - 01/2002
7	Adenocarcinoma 07/2019 - 10/2012
6	Hypertension (High Blood Pressure) 01/2020 - 06/2009
6	Carcinoma (Carcinomatosis) 08/2013 - 02/2004
5	Liver Neoplasms (Liver Cancer) 02/2022 - 12/2013
5	Colorectal Neoplasms (Colorectal Cancer) 11/2021 - 01/2006
4	Liver Diseases (Liver Disease) 02/2022 - 01/2017
4	Sarcoma (Soft Tissue Sarcoma) 11/2021 - 11/2011
4	Triple Negative Breast Neoplasms 08/2021 - 01/2017
4	Edema (Dropsy) 11/2018 - 01/2007
3	Glioma (Gliomas) 10/2018 - 08/2007
3	Obesity 01/2018 - 01/2009
3	Liver Cirrhosis (Hepatic Cirrhosis) 01/2018 - 04/2014
2	Neuroblastoma 01/2022 - 01/2016
2	Medulloblastoma 01/2022 - 02/2013
2	Cholangiocarcinoma 01/2022 - 01/2017
2	Disease Progression 03/2021 - 12/2013
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 12/2020 - 08/2015
2	Acoustic Neuroma (Acoustic Neurinoma) 12/2019 - 10/2016
2	Hearing Loss (Hearing Impairment) 12/2019 - 10/2016
2	Fatigue 10/2019 - 06/2009
2	Fibrosis (Cirrhosis) 01/2018 - 04/2014
2	Carcinogenesis 01/2017 - 06/2016
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2016 - 02/2015
2	Necrosis 04/2016 - 01/2011

Drug/Important Bio-Agent (IBA)

57	Biomarkers (Surrogate Marker)IBA 02/2022 - 11/2005
46	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 08/2002
28	Bevacizumab (Avastin)FDA Link 06/2021 - 02/2004
16	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2020 - 08/2002
12	Sorafenib (BAY 43-9006)FDA Link 04/2021 - 07/2009
10	Pharmaceutical PreparationsIBA 01/2020 - 04/2006
10	cediranib (AZD2171)IBA 01/2017 - 01/2007
9	Immune Checkpoint InhibitorsIBA 01/2022 - 11/2014
9	Angiogenesis InhibitorsIBA 01/2020 - 04/2006
9	Tyrosine Kinase InhibitorsIBA 01/2017 - 01/2006
7	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 09/2009
6	Temozolomide (Temodar)FDA LinkGeneric 01/2020 - 06/2011
6	Fluorouracil (Carac)FDA LinkGeneric 07/2019 - 10/2006
5	cabozantinibIBA 08/2021 - 01/2017
5	Sunitinib (Sutent)FDA Link 09/2015 - 06/2009
5	Phosphotransferases (Kinase)IBA 04/2014 - 01/2006
4	Oxygen (Dioxygen)IBA 01/2022 - 06/2011
4	CytokinesIBA 01/2021 - 10/2009
4	Proteins (Proteins, Gene)FDA Link 09/2020 - 01/2006
4	plerixafor FDA Link 10/2018 - 07/2010
4	CollagenIBA 10/2016 - 05/2009
4	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2016 - 07/2009
4	Chemokine CXCL12IBA 04/2011 - 10/2009
3	Messenger RNA (mRNA)IBA 01/2022 - 01/2016
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2020
3	Neuropilin-1IBA 01/2022 - 10/2009
3	Angiotensin Receptor AntagonistsIBA 01/2022 - 11/2017
3	Losartan (Cozaar)FDA LinkGeneric 01/2022 - 07/2019
3	Cytidine Triphosphate (CTP)IBA 04/2021 - 05/2016
3	Gemcitabine FDA Link 12/2020 - 06/2011
3	Interleukin-6 (Interleukin 6)IBA 12/2020 - 10/2012
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2020 - 07/2009
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2019 - 06/2011
3	Irinotecan (Camptosar)FDA LinkGeneric 07/2019 - 08/2007
3	Protons (Proton)IBA 07/2019 - 07/2014
3	LigandsIBA 05/2017 - 09/2009
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2016 - 09/2009
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2011 - 12/2006
2	Monoclonal AntibodiesIBA 01/2022 - 12/2013
2	Fatty Acids (Saturated Fatty Acids)IBA 11/2021 - 01/2021
2	Insulin-Like PeptidesIBA 04/2021 - 01/2020
2	human ERBB2 proteinIBA 01/2021 - 02/2016
2	Glycoproteins (Glycoprotein)IBA 09/2020 - 01/2006
2	Vascular Endothelial Growth Factor DIBA 01/2020 - 10/2016
2	Lipase (Acid Lipase)FDA Link 01/2020 - 10/2019
2	AntigensIBA 01/2020 - 01/2011
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 02/2016
2	Peptides (Polypeptides)IBA 01/2020 - 01/2019
2	Leucovorin (Folinic Acid)FDA Link 07/2019 - 01/2019
2	Capecitabine (Xeloda)FDA Link 07/2019 - 07/2014
2	Ado-Trastuzumab EmtansineIBA 01/2019 - 02/2016
2	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 02/2016
2	Biological ProductsIBA 11/2018 - 04/2011
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 01/2017
2	AndrogensIBA 01/2017 - 01/2012
2	PlatinumIBA 01/2017 - 06/2011

Therapy/Procedure

74	Therapeutics 01/2022 - 11/2005
24	Radiotherapy 02/2022 - 10/2006
21	Drug Therapy (Chemotherapy) 01/2022 - 11/2005
16	Immunotherapy 01/2022 - 07/2011
8	Aftercare (After-Treatment) 01/2020 - 06/2011
5	Neoadjuvant Therapy 07/2019 - 10/2006
3	Immunomodulation 11/2021 - 10/2015
3	Transplantation 05/2020 - 09/2004
3	Chemoradiotherapy 07/2019 - 09/2007
2	Proton Therapy 01/2018 - 07/2014